Canopy Growth Corp Continues Tweed Main Street Buildout with Invictus MD Strategies Corp (CVE:GENE)

Canopy Growth Corp (TSE:WEED) (OTCMKTS:TWMJF) (FRA:11L1) is adding yet another growing partner to its consumer-facing cannabis product platform with the announced on-boarding of CraftGrow partner AB Laboratories Inc, a subsidiary of Invictus MD Strategies Corp (CVE:GENE) (OTCMKTS:IVITF) That’s the second partner to join the newly minted CraftGrow sub-brand of Tweed Main Street, along with Canada’s Island Garden – Prince Edward Island’s only ACMPR-licensed producer.

Across the Tweed Main Street platform, there are now a total of 8 – 10 sub-brands offering over 50 SKU’s of products ranging from a range of premium dried flower to specialized proprietary formulations that are some of the most consumed brands on the Canadian medical marijuana landscape.

[stock_chart symbol=”WEED:TSX,ACB:TSX,APH:TSX,LEAF:TSX” compare=”percent” width=”100%”]

This explains, in large part, (if you click the one year tab on the performance comparison chart above), why Canopy remains the best-performing cannabis stock from among the Midas Letter Canada Cannabis Composite index constituents. The newly launched index features all Canadian-listed cannabis companies with a market cap over $500 million as of the end of the last calendar quarter.

Bruce Linton shed light on why Canopy Growth Corp is likely to continue on its astonishing growth trajectory as he strives for global domination through the deployment of an international cannabis industry strategy.

The Tweed Main Street platform was conceived as a way for (then) Tweed to allow for distinct brands produced by a range of growers to preserve their identities, allowing customers with strong preferences for certain brands to easily identify their favourites in an increasingly crowded virtual supermarket.

While most of the sub-brands on Tweed Main Street are wholly-owned subsidiaries of Canopy Growth, an increasing number of ACMPR growers are signing up for the platform to ensure a presence among the most robust and diversified product offering in a single location in the Canadian cannabis industry.

“We look at this as a transformative shift in the market,” said Mark Zekulin, President ofCanopy Growth back in March 2017 when the brand was announced. “From doctors to patients to virtually every stakeholder in the sector, we have heard continually that variety, reliability and consistency, matched with high quality products and top customer care are essential. Bringing the sector’s three leading producers into a single online marketplace is the most important thing we can do to serve our clients.”

Canopy’s continued dominance of the Canadian market in terms of availability of strains and associated merchandise suggests that it is the most well-positioned among the Canadian LP’s for the onset of recreational rules, set to take effect later this year.


James West

Editor and Publisher

James West founded Midas Letter in 2008 and has since been covering the best of Canadian and US small cap companies. He covers global economics, monetary policy, geopolitical evolution, political corruption, commodities, cannabis and cryptocurrencies. As an active market participant, James is not a journalist and is invariably discussing markets...
More Info...

[email protected]

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.